Artiva Biotherapeutics Files Prospectus To Offer Up To $400M In Securities
-SEC Filing
Stocks · News reference
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Artiva Biotherapeutics, Inc. (ARTV)
Filed: 2026-07-22 AccNo: 0001193125-26-312560 Size: 168 KB Item 8.01: Other Events
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target
Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
- SEC Filing
Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants
- SEC Filing
Cellectar Biosciences 13G Filing Shows SilverArc Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 851,285 Shares And Warrants